Moderna, Inc.

MRNA · NASDAQ · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$47K – $79K 6 disclosures · 4 bought / 2 sold · last Aug 28, 2026
Ro Khanna D · HOUSE · CA	−$300K – $316K −$838K – $786K today 41 filings · last Aug 24, 2026
Robert Bresnahan R · HOUSE · PA	−$14K – $14K −$116K – $82K today 2 filings · last Apr 8, 2025
Maria Elvira Salazar R · HOUSE · FL	−$29K – $13K −$31K – $15K today 3 filings · last Sep 24, 2026
Josh Gottheimer D · HOUSE · NJ	−$89K – $9K −$147K – $10K today 7 filings · last Feb 1, 2024

Recent transactions

Trades from Jun 29, 2023 – Aug 28, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Buy	41 days Aug 28, 2026 → Oct 8, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	43 days Aug 26, 2026 → Oct 8, 2026	≥$15K
Donald Trump R · EXECUTIVE	Buy	45 days Aug 24, 2026 → Oct 8, 2026	≥$1K
Maria Elvira Salazar R · HOUSE · FL-27	Sell	13 days Sep 24, 2026 → Oct 7, 2026	≥$1K
Maria Elvira Salazar R · HOUSE · FL-27	Buy	21 days Aug 19, 2026 → Sep 9, 2026	≥$1K
Maria Elvira Salazar R · HOUSE · FL-27	Sell	21 days Aug 19, 2026 → Sep 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	11 days Aug 24, 2026 → Sep 4, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	32 days Aug 3, 2026 → Sep 4, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	6 days Jun 30, 2026 → Jul 6, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	44 days May 18, 2026 → Jul 1, 2026	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

866

13F shares

324.9M

Total invested

$22.7B

Ownership

82.2%

New positions

154

Closed positions

Increased positions

406

Reduced positions

255

Put/Call ratio

1.01

Holder	Reported	Shares	Value	Δ Qtr
FMR LLC	8/13/2026	51.9M	$3.6B	+13.55%
BLACKROCK, INC.	8/7/2026	30.6M	$2.1B	+3.25%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	23.2M	$1.6B	+1.47%
CAPITAL WORLD INVESTORS	8/12/2026	22.3M	$1.6B	+19.14%
BAILLIE GIFFORD & CO	8/6/2026	18.2M	$1.3B	−8.90%
STATE STREET CORP	9/22/2026	15.7M	$1.1B	+5.82%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	15.6M	$1.1B	−0.22%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	9.7M	$678.8M	+2.92%
MORGAN STANLEY	8/13/2026	9.5M	$668.0M	+12.59%
THELEME PARTNERS LLP	8/13/2026	8.1M	$564.3M	+0.12%
TWO SIGMA INVESTMENTS, LP	8/14/2026	7.2M	$503.8M	−20.83%
INVESCO LTD.	8/14/2026	5.8M	$404.8M	+20.81%
SUSQUEHANNA INTERNATIONAL GROUP, LLP	8/14/2026	5.7M	$398.6M	−19.07%
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	5.6M	$391.4M	+656.80%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	4.8M	$338.9M	+2.21%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	4.8M	$338.9M	—
GOLDMAN SACHS GROUP INC	8/14/2026	4.7M	$327.2M	−29.25%
FLAGSHIP PIONEERING INC.	8/14/2026	4.6M	$324.4M	+0.00%
UBS GROUP AG	8/13/2026	4.5M	$312.6M	+1.25%
SUSQUEHANNA INTERNATIONAL GROUP, LLP	8/14/2026	4.4M	$310.8M	−19.13%
BNP PARIBAS ARBITRAGE, SNC	8/13/2026	4.4M	$306.5M	+1.39%
JANE STREET GROUP, LLC	8/14/2026	4.2M	$290.8M	−8.09%
TOROSO INVESTMENTS, LLC	8/13/2026	3.9M	$269.6M	−22.72%
JANE STREET GROUP, LLC	8/14/2026	3.1M	$214.5M	+9.54%
CITADEL ADVISORS LLC	9/2/2026	3M	$211.9M	−15.99%

Insider transactions

Insider	Type	Transacted	Price	Date
Hoge Stephen	S-SALE	39.1K	$220.72	Oct 15
Hoge Stephen	M-EXEMPT	76.5K	$12.21	Oct 15
Hoge Stephen	M-EXEMPT	76.5K	$12.21	Oct 15
Hoge Stephen	S-SALE	450	$214.15	Oct 14
Hoge Stephen	M-EXEMPT	76.5K	$12.21	Oct 14
Hoge Stephen	M-EXEMPT	76.5K	$12.21	Oct 14
Hoge Stephen	S-SALE	38.8K	$213.47	Oct 14
Andres Juan		0	—	Oct 5
Mock James M	M-EXEMPT	1.5K	—	Oct 5
Mock James M	M-EXEMPT	1.5K	—	Oct 5

Analyst consensus

Hold29 analysts

Bearish · 6 · Hold · 15 · Bullish · 8

Earnings history

	EPS	Estimate
Q3 2024	$0.03	$-1.91	Beat
Q4 2024	$-2.50	$-2.68	Beat
Q1 2025	$-2.52	$-2.92	Beat
Q2 2025	$-2.13	$-2.99	Beat
Q3 2025	$-0.51	$-1.87	Beat
Q4 2025	$-2.11	$-2.54	Beat
Q1 2026	$-3.40	$-4.45	Beat
Q2 2026	$-1.97	$-2.03	Beat

Peers

Company overview

IPO dateDec 7, 2018

CEOStéphane Bancel

Employees4,700

SectorHealthcare

IndustryBiotechnology

CountryUS

ExchangeNASDAQ Global Select

Websitewww.modernatx.com

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.